Presentation on theme: "PH Pulmonary Hypertension. PH Pulmonary hypertension is an abnormal elevation of the pulmonary artery pressure (PAP) and the pulmonary vascular resistance."— Presentation transcript:
PH Pulmonary Hypertension
PH Pulmonary hypertension is an abnormal elevation of the pulmonary artery pressure (PAP) and the pulmonary vascular resistance (PVR) resulting in right ventricular (RV) failure and premature death.
PH PH used to be recognized as a disease with a grim prognosis. Over the last decade, new medications have been developed to treat PH. These medications have improved both the quantity and quality of life for patients with PH. Since we can now treat PH, we need to be more aware of pursuing it as a diagnosis.
PH What is PH? mPAP > 25 mmHg at rest mPAP > 30 mmHg with activity What are the most common symptoms? Worsening SOB Chest pain Fatigue Palpitations Lower extremity edema Syncope
PH WHO classification Group I- PAH Group II- PVH, PH secondary to LV failure Group III- PH associated with lung disease or hypoxia Group IV- PH secondary to chronic thromboembolic disease Group V- miscellaneous - HIV infection, drug exposure
PH Group I - PAH Replaces primary pulmonary hypertension No known underlying risk factors Usually seen in women of childbearing age Rare - 2 to 3 per million per year Genetic predisposition
PH Facts: Group II – PVH – most common, PCWP >15 mmHg Group III - lung disease COPD – mild PH seen in up to 50% of pts OSA – usually associated with mild PH OHS – more commonly seen with cor pulmonale Group IV - chronic PTED – up to 4%
PH Pathophysiology Pulmonary endothelial cell dysfunction or injury causing vascular changes Intimal proliferation Hypertrophy Proliferation of smooth muscle cells Vasoconstriction In situ thrombosis
PH Making the diagnosis High index of suspicion PE – early, Nl; increased P2, TR, heptojugular reflux CXR, CT chest – enlarged PAs EKG – V1, tall R wave and short S wave (RV hypertrophy); II, p-pulmonale (RAE) Transthoracic ECHO – evaluate LV function, estimate RVSP and PAPS Right heart catheterization – measure PAPs and PCWP
PH Further Evaluation Lab – ANA, RF, HIV, CBC, LFTs, TFTs PFTs – OLD or ILD; decrease in DLCO Overnight oximetry – desaturation is seen in 70% of pts PSG V/Q scan, CT chest, pulmonary angiography
PH Treatment – General measures O2 – keep sats > 90% Avoid vasoconstricting decongestants, B blockers, stimulants and anorexigens Do low level aerobic exercise Follow a low sodium (<2400 mg) diet Avoid pregnancy Anticoagulation Diuretics Digoxin?
PH Prostanoids – prostacyclin analogues Prostacyclin is a potent vasodilator and antiplatelet agent Deficient in pts with PH Improve symptoms Improve hemodynamics Overdosage causes hypotension and hyperdynamic state with high-output cardiac failure
PH Prostanoids cont. Epoprostenol – only drug with proven survival benefit; 6 minute half-life Must be kept cold during storage and administration Continuous IV infusion thru tunneled catheter Treprostinil – not shown to improve survival; 3 hour half life Continuous SQ infusion Iloprost – inhaled route of administration; 6-9 times a day (Q2 hours while awake)
PH PDE-5s – improve sx and functional class; augments vasodilatory effects of nitric oxide Sildenafil (Revatio) – oral, TID HAs Flu-like sx Flushing Epistaxis
PH NYHA classification of functional status of pts with PH I – no limitations in nl physical activity II – mild limitation, no sx at rest, worsening sx with exertion III – marked limitation, no sx at rest, worsening sx with light activity IV – sx at rest, unable to do any activity, signs of RV failure at rest
PH Treatment by Classification I – monitor II – oral sildenafil (Revatio) III – oral sildenafil or bosentan (Tracleer) and inhaled or intravenous prostanoids IV – intravenous prostanoids
PH Goals of Treatment Improvement to class I or II Improvement in the 6 MWDT to 380 m or better Max SBP with exercise of 120 mm Hg or greater Decrease in BNP to < 180 pg/ml
PH Other treatments Surgery Atrial septostomy – decrease right-sided pressures, may worsen hypoxia Lung transplant – curative, post op median survival 5 years Pulmonary thromboendarterectomy – curative for PH from chronic PTED, tx of choice in appropriate candidates
PH Upcoming therapies Treprostinil – infusion and inhaled available now, working on oral formulation Sitaxsentan – approved in Europe, application is pending with FDA Tadalafil (Cialis) – longer half-life and greater selectivity and potency than sildenafil; in trials now
PH Prognosis 1980s – grim, medial survival of 2.8 years from time of diagnosis in untreated pts Current – newer medications have greatly improved the outlook for pts with PH Poor prognostic indicators – low 6 MWDT; pericardial effusion, RV dysfunction, and RAE on ECHO; increased mRAP (the most powerful hemodynamic predictor) and decreased cardiac index on RHC; and elevated BNP